14 results
In the first place, we will collect tissues from over-reacting patients, including a thorough quality assurance program. Thereafter, we will identify the gene profiles of the patients that exhibit extreme radio-sensitivity without known hereditary…
To determine the maximum tolerated dose (MTD), dose limiting toxicities (DLT), and optimal dose of docetaxel that can safely be administered to patients with cancer in a weekly schedule. amendment 1The objective of the first amendment is to…
To determine the improvement in symptoms of constipation in subjects receiving treatment with oxycodone/naloxone prolonged release tablets (OXN) compared to subjects receiving oxycodone prolonged release tablets (OXY) based on the Bowel Function…
To study the influence of hepatic impairment on plasma pharmacokinetic parameters of eribulin mesylate (E7389) following an IV administration.
To determine if PHA-739358 has an antitumor activity against breast, ovaria, pancreatic, colerectal, small and non small cell squamous lung cancer.
The aim is to study if Neurofeedback can be an applicable intervention.for survivors of childhood brain tumours. The QEEG wil be investigated whether under or overactive brainareas exist which can be trained. This study will also investigate whether…
The objective of this study is to determine the effectiveness of receiving a multidisciplinary protocolized patient-tailored treatment of physical symptoms (PPT) in combination with structurally monitoring of reported symptoms (the intervention) on…
To identify novel childhood cancer-predisposing genes in children.
Primary objectives:1) To determine whether concurrent ATII-antagonist treatment can prevent trastuzumab-related cardiotoxicity, defined as a decline in LVEF of more than 15% or a decrease to an absolute value <45%Secondary objectives:1) To…
To determine the feasibility of a trainingprogram in childhood cancer survivors in the primary health care system
Primary: To demonstrate the superior efficacy of Nasalfent in the treatment of BTCP in opioid tolerant subjects who are receiving regular opioid therapy.Secondary: To demonstrate the safety, tolerability, and acceptability of Nasalfent in the…
The question is whether aprepitant should be added to CE cycles (cisplatin containing regimen with etoposide) because of a possible interaction between aprepitant and etoposide.This question derives from the fact that both drugs are metabolised…
This study will focus on the nutritional problems described above of children treated for cancer. The study will describe: the nutritional state during treatment, the determinants affecting the nutritional intake and the impact of nutritional…
Primary• To determine the safety profile of oral topotecan in subjects with cancer andmildly moderately or severely impaired renal function (Groups C, D and E) compared to subjects with cancerwhose renal function is normal and who have received…